Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 16/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | FNTA | P49354 | 2/20 | 0.36 |
| ▸ | FNTB | P49356 | 2/20 | 0.36 |
| ▸ | PGGT1B | P53609 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL7407444 | 1.00 | F10 (0.52) | F10GAAALOX12SMN1; SMN2FNTA | |
| Trifluoroacetic Acid SCHEMBL7537111 | 0.91 | F10 (0.60) | F10FNTAFNTBPGGT1BCYP3A4 | |
| Trifluoroacetic Acid SCHEMBL7537108 | 0.91 | F10 (0.60) | F10FNTAFNTBPGGT1BCYP3A4 | |
| Trifluoroacetic Acid SCHEMBL6224226 | 0.91 | F10 (0.60) | F10FNTAFNTBPGGT1BCYP3A4 | |
| Trifluoroacetic Acid SCHEMBL6223341 | 0.91 | F10 (0.42) | F10GAAALOX12SMN1; SMN2FNTA | |
| Trifluoroacetic Acid SCHEMBL6223344 | 0.91 | F10 (0.42) | F10GAAALOX12SMN1; SMN2FNTA | |
| Trifluoroacetic Acid SCHEMBL7537550 | 0.81 | F10 (0.47) | F10SMN1; SMN2FNTAFNTBPGGT1B | |
| Trifluoroacetic Acid SCHEMBL7407257 | 0.81 | F10 (0.47) | F10SMN1; SMN2FNTAFNTBPGGT1B | |
| Trifluoroacetic Acid SCHEMBL7376661 | 0.80 | F10 (0.45) | F10 | |
| Trifluoroacetic Acid SCHEMBL7540711 | 0.79 | F10 (0.42) | F10DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020013310-A1 | Sulfonic acid or sulfonylamino N-(heteroaralkyl)-azaheterocyclylamide compounds | AVENTIS PHARMACEUTICALS PRODUCTS INC. | 2002-01-31 | — | — | US | claimed |
| US-6281227-B1 | INHIBITORS OF THE ACTIVITY OF FACTOR XA. | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2001-08-28 | — | — | US | claimed |
| US-20020013310-A1 | Sulfonic acid or sulfonylamino N-(heteroaralkyl)-azaheterocyclylamide compounds | AVENTIS PHARMACEUTICALS PRODUCTS INC. | 2002-01-31 | — | — | US | disclosed |
| EP-1086099-A4 | SULFONIC ACID OR SULFONYLAMINO N-(HETEROARALKYL)-AZAHETEROCYCLYLAMIDE COMPOUNDS | AVENTIS PHARM PROD INC (US) | 2002-01-02 | — | — | EP | disclosed |
| US-6281227-B1 | INHIBITORS OF THE ACTIVITY OF FACTOR XA. | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2001-08-28 | — | — | US | disclosed |
| EP-1086099-A1 | SULFONIC ACID OR SULFONYLAMINO N-(HETEROARALKYL)-AZAHETEROCYCLYLAMIDE COMPOUNDS | Aventis Pharmaceuticals Products Inc. (US) | 2001-03-28 | — | — | EP | disclosed |
| WO-1999062904-A1 | SULFONIC ACID OR SULFONYLAMINO N-(HETEROARALKYL)-AZAHETEROCYCLYLAMIDE COMPOUNDS | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 1999-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020013310-A1 | Sulfonic acid or sulfonylamino N-(heteroaralkyl)-azaheterocyclylamide compounds | STS, ARSA, F12 | F10 20/4885GAA 101/4885ALOX12 787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.